AngioDynamics' NanoKnife® System Recognized in TIME's 2025 Best Inventions List
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 13 2025
0mins
Should l Buy ANGO?
Source: Newsfilter
Recognition of NanoKnife System: AngioDynamics' NanoKnife System has been named one of TIME's 2025 Best Inventions for its innovative use of Irreversible Electroporation (IRE) technology in treating prostate tumors, offering a minimally invasive alternative to traditional cancer treatments.
Clinical Efficacy and Safety: The NanoKnife System has shown promising results in clinical studies, with 84% of patients free from significant disease after 12 months and high preservation rates of urinary and sexual function, supporting its FDA clearance for prostate tissue ablation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANGO
Wall Street analysts forecast ANGO stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.030
Low
16.00
Averages
19.33
High
24.00
Current: 11.030
Low
16.00
Averages
19.33
High
24.00
About ANGO
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AngioDynamics (ANGO) Q3 2025 Earnings Transcript
See More
AngioDynamics (ANGO) Q1 2026 Earnings Transcript
See More
AngioDynamics (ANGO) Q2 2026 Earnings Transcript
See More
AngioDynamics (ANGO) Q1 2025 Earnings Transcript
See More
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
See More
AngioDynamics Reports 8.8% Revenue Growth in Q3 but Shares Plunge 13.1%
- Revenue Growth: AngioDynamics reported Q3 revenue of $79.4 million, an 8.8% year-over-year increase that exceeded Wall Street's expectations of $76.4 million, indicating the company's ongoing growth potential in the medical technology sector.
- Adjusted Loss: The company posted an adjusted loss of $59,000, or approximately $0.00 per share, significantly better than analysts' expectations of a $0.10 loss per share, reflecting a stronger-than-anticipated financial performance.
- Unexpected CEO Retirement: The sudden retirement of CEO Jim Clemmer has created uncertainty in the market, although he will remain in his role until a successor is found, the lack of a pre-identified successor may undermine investor confidence.
- Optimistic Future Outlook: Despite leadership changes, AngioDynamics has raised its net sales and adjusted EBITDA guidance for fiscal year 2026 and received FDA approvals for new devices, demonstrating positive advancements in innovation and market expansion.
See More
AngioDynamics (ANGO) Q3 2025 Earnings Transcript
See More
AngioDynamics (ANGO) Q1 2026 Earnings Transcript
See More
AngioDynamics (ANGO) Q2 2026 Earnings Transcript
See More
AngioDynamics (ANGO) Q1 2025 Earnings Transcript
See More
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
See More
AngioDynamics Reports 8.8% Revenue Growth in Q3 but Shares Plunge 13.1%
- Revenue Growth: AngioDynamics reported Q3 revenue of $79.4 million, an 8.8% year-over-year increase that exceeded Wall Street's expectations of $76.4 million, indicating the company's ongoing growth potential in the medical technology sector.
- Adjusted Loss: The company posted an adjusted loss of $59,000, or approximately $0.00 per share, significantly better than analysts' expectations of a $0.10 loss per share, reflecting a stronger-than-anticipated financial performance.
- Unexpected CEO Retirement: The sudden retirement of CEO Jim Clemmer has created uncertainty in the market, although he will remain in his role until a successor is found, the lack of a pre-identified successor may undermine investor confidence.
- Optimistic Future Outlook: Despite leadership changes, AngioDynamics has raised its net sales and adjusted EBITDA guidance for fiscal year 2026 and received FDA approvals for new devices, demonstrating positive advancements in innovation and market expansion.
See More
